Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s development programs at the 35th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017 at 1:30 p.m. Pacific Time.
BioCryst’s conference presentation slides will be available for downloading from the BioCryst website events page at noon on Sunday, January 8th Pacific Time at the link below: http://investor.shareholder.com/biocryst/events.cfm. The live audio webcast and a replay of the presentation will also be available at the link above.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
